I do not have access to the specific article from the New England Journal of Medicine that you cited (Volume 394, Number 11, March 12/19, 2026). However, based on the available scientific data comparing apixaban and rivaroxaban in venous thromboembolism, I can provide the following verified information: Patients treated with apixaban had a lower rate of recurrent venous thromboembolism compared to rivaroxaban[1]. Apixaban was associated with a lower risk of bleeding, including intracranial and gastrointestinal bleeding[1]. In a study of nearly 19,000 elderly patients without cancer, the incidence of major bleeding during primary treatment (0-6 months) was 4.4 per 100 patient-years for rivaroxaban and 3.3 per 100 patient-years for apixaban[2]. During secondary treatment (6 months to 5 years), no difference in bleeding risk was found between the two drugs[2]. Apixaban did not show an increased risk of recurrent pulmonary embolism compared to rivaroxaban[2]. The clinical disadvantage of apixaban is the need to take it twice a day for 3-6 months, while rivaroxaban is given once a day after the initial three weeks[1].